Carbios and Novozymes Strengthen Collaboration With Long-Term Exclusive Strategic Partnership to Secure Worldwide Leadership in Biorecycling of PET
12.1.2023 08:45:00 EET | Business Wire | Press release
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230111005921/en/
(L-R) Hans Ole Klingenberg, Vice President, Marketing Agricultural & Industrial Biosolutions, Novozymes; Tina Sejersgård Fanø, Executive Vice President, Agricultural & Industrial Biosolutions, Novozymes; Emmanuel Ladent, CEO, Carbios; Alain Marty, Chief Scientific Director, Carbios (Photo: Business Wire)
Carbios (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastics and textiles, and Novozymes, the world leader in biological solutions, announce today an exclusive long-term global strategic partnership. This major agreement ensures the long-term production and supply of Carbios’ proprietary PET-degrading enzymes at an industrial scale for the world’s first biological PET-recycling plant due to start production in 2025 in Longlaville (France), as well as Carbios’ future licensee customers.
Exclusive Global Partnership
Carbios and Novozymes have had a partnership since 2019 to develop enzyme-based solutions and address the sustainability challenge of plastic pollution, both within PET-recycling1 and PLA-biodegradation2. Building on the current Joint Development Agreement (JDA), under the new agreement, Carbios and Novozymes will extend their collaboration to develop, optimize and produce enzymes that will subsequently be supplied by Novozymes to all licensees of Carbios’ technology. The new agreement grants both parties exclusivity in the field of the partnership.
Large-scale Industrial Deployment
The strategic partnership supports the large-scale industrial deployment of Carbios’ patented PET-recycling technology starting with Carbios’ future industrial reference unit in Longlaville (France), which will be the world’s first biological PET-recycling plant. Construction will begin later this year, and both building and operating permits having been filed with local authorities. Production at the plant is set to start in 2025 and the processing capacity will be 50,000 tonnes of waste per year.
“We are delighted to expand our partnership with Novozymes, the world leader in biological solutions, and to build on our strong existing relationship to provide a sustainable supply solution for our future customers,” commented Emmanuel Ladent, Chief Executive Officer of Carbios. “Novozymes’ continued support is testament to our joint commitment to achieve a truly circular economy for plastics and textiles that will benefit the environment and be economically viable for all business partners.”
“We are excited to advance our collaboration with Carbios by signing this exclusive agreement and to support the next phase of scaling this new business of biological plastic recycling,” said Hans Ole Klingenberg, Vice President, Marketing Agricultural & Industrial Biosolutions of Novozymes. “By providing biological solutions at a large scale, Novozymes is pleased to contribute in bringing Carbios’ biorecycling of PET-plastics and fibers to market.”
About Carbios
Established in 2011 by Truffle Capital, Carbios is a green biotech company, developing biological and innovative processes. Through its unique approach of combining enzymes and plastics, Carbios aims to address new consumer expectations and the challenges of a broad ecological transition by taking up a major challenge of our time: plastic and textile pollution. Carbios deconstructs any type of PET (the dominant polymer in bottles, trays, textiles made of polyester) into its basic components which can then be reused to produce new PET plastics with equivalent quality to virgin ones. This PET innovation, the first of its kind in the world, was recently recognized in a scientific paper published in front cover of the prestigious journal Nature. Carbios successfully started up its demonstration plant in Clermont-Ferrand in 2021. It has now taken another key step towards the industrialization of its process with the construction of a first-of-a-kind unit in partnership with Indorama Ventures.
In 2017, Carbios and L’Oréal co-founded a consortium to contribute to the industrialization of its proprietary recycling technology. Committed to developing innovative solutions for sustainable development, Nestlé Waters, PepsiCo and Suntory Beverage & Food Europe joined this consortium in April 2019. In 2022, Carbios signed an agreement with On, Patagonia, PUMA, and Salomon, to develop solutions promoting the recyclability and circularity of their products.
The Company has also developed an enzymatic biodegradation technology for PLA-based (a bio sourced polymer) single-use plastics. This technology can create a new generation of plastics that are 100% compostable at ambient temperatures, even in domestic conditions, integrating enzymes at the heart of the plastic product.
For more information, please visit www.carbios.com/en / Twitter: Carbios LinkedIn: Carbios Instagram: insidecarbios
Carbios (ISIN FR0011648716/ALCRB) is eligible for the PEA-PME, a government program allowing French residents investing in SMEs to benefit from income tax rebates.
About Novozymes
Novozymes is the world leader in biological solutions. Together with customers, partners, and the global community, we improve industrial performance while preserving the planet's resources and helping build better lives. As the world's largest provider of enzyme and microbial technologies, our bioinnovation enables higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel, and many other benefits that we rely on today and in the future. We call it Rethink Tomorrow. www.power-with-biology.com
Translation is for information purposes only.
In case of discrepancy between the French and the English version of this press release, the English version shall prevail
1 Cf Press release dated 30 January 2020
2 Cf Press release dated 29 January 2019
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230111005921/en/
Contact information
CARBIOS
Melissa Flauraud
Press Relations
melissa.flauraud@carbios.com
Benjamin Audebert
Investor Relations
contact@carbios.com
+33 (0)4 73 86 51 76
Press Relations (Europe)
Iconic
Marie-Virginie Klein
mvk@iconic-conseil.com
+33 (0)1 44 14 99 96
Press Relations (U.S.)
Rooney Partners
Kate L. Barrette
kbarrette@rooneyco.com
+1 212 223 0561
Press Relations (DACH)
MC Services
Anne Hennecke
carbios@mc-services.eu
+49 (0)211 529 252 22
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Even Realities Brings Classic Tortoiseshell Design to Smart Glasses with New Even G2 Brown 226.10.2026 16:00:00 EET | Press release
Even Realities, the company behind camera-free, display-first smart glasses, today introduced Brown 2, a new tortoiseshell-inspired colorway for Even G2, alongside two accessories: Even G2 Clip (Polarized) and the Even G2 Chain. Designed to bring the warmth and character of traditional tortoiseshell eyewear to smart glasses, Brown 2 features a newly developed material that carries its layered pattern throughout the frame rather than applying it as a surface finish. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026502782/en/ Even G2 Chain. Photo Credit: Even Realities Each frame is individually shaped, pressed, tumbled, and polished for 20 hours, creating subtle variations that make every pair unique. Brown 2 is also the lightest Even G2 design to date, while retaining the camera-free, display-first technology that brings live translation, notifications, and a teleprompter directly into the wearer's field of view. "For sm
Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 202626.10.2026 15:45:00 EET | Press release
Incyte (Nasdaq:INCY) announced new results from its advancing oncology portfolio, including updated results for its KRAS G12D inhibitor (INCB161734) in pancreatic ductal adenocarcinoma (PDAC) and advanced or metastatic colorectal cancer (CRC), and its TGFβR2×PD-1 bispecific antibody (INCA338901) in microsatellite stable CRC (MSS CRC). The data were featured in three rapid oral sessions (Abstract #3137RO, Abstract #1007RO and Abstract #1954RO, respectively) at the European Society of Medical Oncology (ESMO) Congress 2026. “At Incyte we are focused on improving outcomes for people living with cancer. The data presented for INCB161734 and INCA33890 show the potential of both programs to improve the standard-of-care in hard-to-treat diseases,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. “Across pancreatic and colorectal cancers, we continue to see encouraging evidence of clinical activity and manageable safety profiles, supporting the promise
Bending Spoons Completes the Acquisition of Miro26.10.2026 15:00:00 EET | Press release
Bending Spoons S.p.A. (NASDAQ: BSP) has completed the previously announced acquisition of Miro, the visual collaboration platform used by more than 250,000 organizations to brainstorm, plan, and build together. “Miro has built a strong business around a product that makes complex collaborative work feel simple,” said Luca Ferrari, Bending Spoons CEO and co-founder. “Miro’s versatility has made it useful across a broad range of industries and workflows, while creating a robust foundation for further expansion. We believe there’s significant potential to build on these strengths. We look forward to drawing on Bending Spoons’ technologies and expertise to make Miro even more useful to customers and support its continued growth.” “Teams depend on Miro for innovating, alignment, coordination, and decisioning, and that need is only growing,“ said Andrey Khusid, CEO and co-founder of Miro. “In Bending Spoons, Miro has an owner who invests for the long term and cares deeply about product quali
Dubai Culture Opens Registration for ISEA2026 Dubai26.10.2026 14:09:00 EET | Press release
Dubai Culture and Arts Authority (Dubai Culture) has opened registration for the 31st International Symposium on Electronic/Emerging Art (ISEA2026 Dubai), taking place from 6 to 15 November 2026 under the theme ‘ELYAH: Constellating Place, Data and Identity’. The symposium will be the largest edition to date, bringing together artists, researchers, and innovators from around the world to explore the intersection of art, science, and technology and exchange perspectives on the future of contemporary creative practice. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026652826/en/ Dubai Culture Opens Registration for ISEA2026 Dubai (Graphic: AETOSWire) The event supports Dubai Culture’s efforts to advance the digital arts ecosystem, deliver on its Digital Arts Roadmap objectives, and empower local talent. It also reinforces Dubai’s position as a global cultural reference, a leader in innovation, a driver of the creative econo
Agendia Unveils Clinical Validation of AI-Driven Digital Pathology Approach26.10.2026 14:00:00 EET | Press release
Agendia, Inc., a leader in precision oncology for breast cancer, recently presented research introducing its investigational artificial intelligence (AI)-driven digital pathology approach for the MammaPrint®70-gene recurrence signature at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid. The podium presentation, delivered by co-founder and Chief Research Officer, Laura van ’t Veer, Ph.D., detailed the development and clinical validation of a deep learning pipeline that can infer MammaPrint (MP) risk categories directly from hematoxylin and eosin (H&E)-stained, whole-slide images (WSIs). The company also presented two additional posters highlighting data from the prospective, real-world FLEX Study (NCT03053193). “AI has been part of Agendia’s scientific foundation from the beginning and this study represents its continued evolution,” said Dr. Laura van ‘t Veer. "For the first time, we are presenting our work exploring whether the biological information represente
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom